Canaccord raises Estee Lauder stock price target on earnings beat By Investing.com

Estée Lauder beat fiscal Q3 2026 expectations with sales up 4.6% year over year and adjusted EPS of $0.91 versus $0.65 consensus, while lifting full-year EPS guidance by $0.25 at the midpoint. Management said the Iran conflict could create about a $0.06 EPS headwind and a two-point sales drag, but also pointed to market share gains in Mainland China, broad-based category growth, and ongoing cost-cutting under One ELC. Canaccord raised its price target to $85 from $80, while Barclays increased its target to $75 from $72.

Analysis

EL’s beat is more important for the speed of the turnaround than the headline magnitude: the mix is improving while guidance was raised into a macro tape that is still selectively punishing consumer staples. That combination usually matters more to the multiple than a single quarter’s EPS surprise because it reduces the market’s fear that this is just inventory normalization. The key second-order read-through is that prestige beauty demand is proving resilient enough to absorb both restructuring friction and regional disruptions, which should pressure lower-quality competitors with less pricing power and weaker China exposure.

The bigger setup is that one of the most derated global consumer brands is now showing operating leverage before the cost cuts are fully embedded. If management can keep delivering even low-single-digit top-line growth while margins expand, the stock can rerate from “value trap” toward “self-help compounder” over the next 2–4 quarters. That said, the current move may already be pricing in an unreasonably clean recovery path; in beauty turnarounds, the market typically overweights early evidence and underweights how often regional demand and launch cycles interrupt linear improvement.

The geopolitics angle is a near-term risk, not a thesis breaker. A small EPS hit from Middle East disruption is manageable, but the real danger is second-order: travel retail, Asia tourist flows, and replenishment cadence can soften simultaneously if conflict keeps headlines hot for 1–2 quarters. That makes the name more attractive on dips than on strength, especially if the market starts extrapolating 2027 growth too aggressively before the China and US channels prove durability.

Key Decisions for Investors

• Buy EL on 2-3% pullbacks over the next 1-2 weeks; target a 10-15% move over 3-6 months if guide raises continue and margin expansion holds. Risk/reward is favorable as long as the stock stays above the prior support zone near the high-70s.
• Use EL as a relative long against a slower-turning global consumer or discretionary basket: long EL / short a basket of lower-quality beauty or premium consumer names with weaker China exposure. The trade works if the market rewards visible self-help and punishes weaker operating leverage over the next quarter.
• For hedged exposure, sell cash-secured puts on EL with 2-3 month expiry and strikes 5-8% below spot. This captures elevated implied optimism while positioning to own the stock only if the market gives back post-earnings gains.
• Avoid chasing upside via outright calls here; the better asymmetry is waiting for a retest after the market digests the raised guidance and geopolitics. The risk is not thesis failure, but multiple compression if investors decide the recovery is already priced.
• Monitor luxury/beauty peers for sympathy upside and use any broad sector strength to fade weaker names. EL’s improving execution may widen dispersion within prestige beauty, creating a cleaner long/short opportunity than a directional sector bet.